Mark Warren, MD: In the SWITCH 1 and SWITCH 2 trials, glargine and degludec were compared in a crossover fashion. The SWITCH 1 trial involved patients with type 1 diabetes; SWITCH 2 involved patients with type 2. And all these patients were patients who were high risk for hypoglycemia. So, we enriched the trial with patients who were at higher risk for hypoglycemia, and the goal was to see if there’s any differences in hypoglycemia between degludec and U100 glargine insulin. What we found was a very consistent reduction in hypoglycemia with degludec compared with U100 glargine, anywhere from 30% to 50%. There was 40% less nocturnal hypoglycemia and 50% less severe hypoglycemia, which goes along with what we thought would happen since these insulins have less variability in their absorption from day to day.
The clinical trials ultimately showed us that degludec gives a significant reduction in hypoglycemia, clinically significant as well as statistically significant. They’re extremely important when we treat diabetes, and these are patients who, again, had a higher risk of hypoglycemia. Just the reduction in nocturnal hypoglycemia is very important, because patients really have a phobia of nocturnal hypoglycemia, because they’re not alert and awake and they’re afraid of having a severe episode of hypoglycemia at night. So, they tend to preempt that by eating more, taking less insulin, etc. These are very important findings in the SWITCH 1 and SWITCH 2 studies.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More